Annovis Bio, Inc. (NYSE: ANVS) has announced that the New York Stock Exchange (NYSE) has accepted its plan to regain compliance with listing standards, following a noncompliance notice dated March 26, 2025. The company is granted an 18-month period to address issues related to market capitalization and stockholders’ equity.
As part of the compliance plan, Annovis is required to provide quarterly updates on its progress. The acceptance allows the company to retain its stock listing and continue operations, though failure to meet requirements within the compliance period could lead to potential suspension of trading.
During the most recent quarter, 28 institutional investors added shares of ANVS, while 13 decreased their positions.
